Abstract:Aberrant reactivation of Hedgehog (Hh) signaling has been described in a wide variety of human cancers and its role in maintenance of self-renewal of cancer stem cells. We previously showed that Indian Hh (Ihh) and its receptor molecules, Patched and Smoothened are expressed in cord blood (CB) CD34+ cells and Ihh regulate proliferation of hematopoietic myeloid- and lymphoid-repopulating cells in vivo. However, the involvement of Hh signaling in proliferation of leukemic cells has remained unclear. In this study, we assessed the possibility that Hh pathway activation contributes to the growth, survival and drug resistance of acute myeloid leukemic (AML) cells. Hh signaling in leukemic cell lines and bone marrow (BM) CD34+ cells were screened by RT-PCR and a Hh signaling reporter assay. We have found that Ihh were expressed in BM CD34+ cells and most of human AML cell lines, HL60, U937, KG1, Kasumi-1, Kasumi3 and TF-1. In contrast, Hh receptor components, Patched and Smoothened, were detected in BM CD34+ cells and cytokine responsible CD34+ AML cell lines such as Kasumi-1, Kasumi-3 and TF-1. Moreover, the downstream transcription factor GLI1 or GLI2 were expressed in BM CD34+ cells and these CD34+ cell lines, indicating that Hh signaling was active in these cells. We further assessed whether Hh signaling transmit to GLI1 using GLI1-responsive luciferase assay. GLI-responsive reporter plasmid (TK-6GBS-Luc) was transduced into these cells in the presence or absence of anti-Hh neutralizing antibody 5E1. TK-6GBS-Luc-transduced Kasumi-1, Kasumi-3 and TF-1 cells showed high luciferase activity. Furthermore, the luciferase activity of these cells was significantly reduced in the presence of 10 μg/ml anti-Hh neutralizing antibody. These results clearly indicate that Ihh signaling transmits into these CD34+ leukemic cell lines in autocrine manner. We next examined the effect of Hh inhibitors on these CD34+ leukemic cell lines. Inhibition of Hh signaling with the naturally derived chemical Smoothened antagonist Cyclopamine, endogenous Hh inhibitor Hedgehog-interacting protein or anti-Hedgehog neutralizing antibody reduces the entry of cell cycle of CD34+ cell lines and eventually induces apoptosis in these cells after 48 hr exposure although these CD34+ cell lines exhibit resistance to cytarabine (Ara-C) exposure. In contrast, cyclopamine did not affect growth and survival of the U937 or HL-60 cell line that lacks expression of Hh receptor components. Furthermore, combination of 10 μM cyclopamine significantly reduced the drug resistance against Ara-C in CD34+ cell lines. These results suggest that Hh pathway activation is a feature of CD34+ myeloid leukemic cells and inhibition of Hh signaling pathway may be a therapeutic strategy in the treatment of AML.

Blocking the hedgehog pathway inhibits hepatoblastoma growth

Hedgehog Signaling in Human Hepatocellular Carcinoma

MEKK2 and MEKK3 Suppress Hedgehog Pathway-Dependent Medulloblastoma by Inhibiting GLI1 Function

Activation of the Hedgehog Pathway in Human Hepatocellular Carcinomas

Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma

Prognostic value of hedgehog signal component expressions in hepatoblastoma patients

Hedgehog signaling pathway activation in hepatocellular carcinoma

HHIP Gene Overexpression Inhibits the Growth, Migration and Invasion of Human Liver Cancer Cells.

Role of the Hedgehog Pathway in Hepatocellular Carcinoma (Review).

Inhibition of Hedgehog Delays Liver Regeneration through Disrupting the Cell Cycle

Overexpression of UHRF1 promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma

Activation of Sonic Hedgehog Signaling Pathway is an Independent Potential Prognosis Predictor in Human Hepatocellular Carcinoma Patients

Suppression of Growth and Migration by Blocking the Hedgehog Signaling Pathway in Gastric Cancer Cells

Partial Hepatectomy Promotes Implanted Mouse Hepatic Tumor Growth By Activating Hedgehog Signaling

Hedgehog components are overexpressed in a series of liver cancer cases

Therapeutic Inhibition of Phospholipase D1 Suppresses Hepatocellular Carcinoma.

Sonic hedgehog signaling pathway mediates development of hepatocellular carcinoma

IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors

Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor Hpi-1 (nanohhi) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma

Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis.

Hedgehog Inhibitors Reduce the Survival and Drug Resistance in CD34+ Leukemic Cells.